Description

Simple

Clinical

Overview

Pharmacology

Indication

Investigated for use/treatment in herpes zoster infections and viral infection.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Valomaciclovir
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Valomaciclovir.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Valomaciclovir.
3,5-Diiodotyrosine
3,5-Diiodotyrosine may decrease the excretion rate of Valomaciclovir which could result in a higher serum level.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Valomaciclovir.
6-Deoxyerythronolide B
The metabolism of Valomaciclovir can be decreased when combined with 6-Deoxyerythronolide B.
7-Nitroindazole
7-Nitroindazole may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.
Abiraterone
The serum concentration of Valomaciclovir can be increased when it is combined with Abiraterone.
Acebutolol
The risk or severity of adverse effects can be increased when Acebutolol is combined with Valomaciclovir.
Acetazolamide
Acetazolamide may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.
Adalimumab
The serum concentration of Valomaciclovir can be decreased when it is combined with Adalimumab.
Adenosine
The therapeutic efficacy of Adenosine can be decreased when used in combination with Valomaciclovir.
Adinazolam
The therapeutic efficacy of Adinazolam can be decreased when used in combination with Valomaciclovir.
Albinterferon Alfa-2B
The metabolism of Valomaciclovir can be decreased when combined with Albinterferon Alfa-2B.
Allopurinol
The serum concentration of Valomaciclovir can be increased when it is combined with Allopurinol.
Alprazolam
The therapeutic efficacy of Alprazolam can be decreased when used in combination with Valomaciclovir.
Alprenolol
The risk or severity of adverse effects can be increased when Alprenolol is combined with Valomaciclovir.
Amobarbital
The serum concentration of Valomaciclovir can be decreased when it is combined with Amobarbital.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Valomaciclovir.
Anisodamine
The risk or severity of adverse effects can be increased when Anisodamine is combined with Valomaciclovir.
Arotinolol
The risk or severity of adverse effects can be increased when Arotinolol is combined with Valomaciclovir.